Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Revolution Medicines Inc.COM | COM | $1.19B | 22.3% |
| Nuvalent Inc.COM | COM | $732M | 13.7% |
| Edgewise Therapeutics Inc.COM | COM | $415M | 7.8% |
| Genmab A/sSPONSORED ADS | SPONSORED ADS | $361M | 6.8% |
| Spyre Therapeutics Inc.COM NEW | COM NEW | $341M | 6.4% |
| Apogee Therapeutics Inc.COM | COM | $209M | 3.9% |
| Oruka Therapeutics Inc.COM | COM | $204M | 3.8% |
| Tango Therapeutics Inc.COM | COM | $199M | 3.7% |
| Belite Bio Inc.SPONSORED ADS | SPONSORED ADS | $190M | 3.6% |
| Erasca Inc.COM | COM | $175M | 3.3% |
| Tarsus Pharmaceuticals Inc.COM | COM | $175M | 3.3% |
| Alnylam Pharmaceuticals Inc.COM | COM | $144M | 2.7% |
| Insmed Inc.COM PAR $.01 | COM PAR $.01 | $141M | 2.6% |
| Mbx Biosciences Inc.COM | COM | $138M | 2.6% |
| Vaxcyte Inc.COM | COM | $124M | 2.3% |
| Viridian Therapeutics Inc.COM | COM | $124M | 2.3% |
| Olema Pharmaceuticals Inc.COM | COM | $108M | 2.0% |
| Jade Biosciences Inc.COM NEW | COM NEW | $63.5M | 1.2% |
| Tyra Biosciences Inc.COM | COM | $58.4M | 1.1% |
| Assembly Biosciences Inc.COM NEW | COM NEW | $42.7M | 0.8% |
| Eyepoint Inc.COM NEW | COM NEW | $41.3M | 0.8% |
| Achieve Life Science Inc.COM | COM | $32.3M | 0.6% |
| Vor Biopharma Inc.COM NEW | COM NEW | $32.2M | 0.6% |
| Maplight Therapeutics Inc.COM | COM | $24.6M | 0.5% |
| Kardigan Inc.COM | COM | $21.5M | 0.4% |
| Lexeo Therapeutics Inc.COM | COM | $19.4M | 0.4% |
| Editas Medicine Inc.COM | COM | $18.1M | 0.3% |
| Inventiva SAADS | ADS | $15.1M | 0.3% |
- Class
- COM
- Share
- 22.3%
- Class
- COM
- Share
- 13.7%
- Class
- COM
- Share
- 7.8%
- Class
- SPONSORED ADS
- Share
- 6.8%
- Class
- COM NEW
- Share
- 6.4%
- Class
- COM
- Share
- 3.9%
- Class
- COM
- Share
- 3.8%
- Class
- COM
- Share
- 3.7%
- Class
- SPONSORED ADS
- Share
- 3.6%
- Class
- COM
- Share
- 3.3%
- Class
- COM
- Share
- 3.3%
- Class
- COM
- Share
- 2.7%
- Class
- COM PAR $.01
- Share
- 2.6%
- Class
- COM
- Share
- 2.6%
- Class
- COM
- Share
- 2.3%
- Class
- COM
- Share
- 2.3%
- Class
- COM
- Share
- 2.0%
- Class
- COM NEW
- Share
- 1.2%
- Class
- COM
- Share
- 1.1%
- Class
- COM NEW
- Share
- 0.8%
- Class
- COM NEW
- Share
- 0.8%
- Class
- COM
- Share
- 0.6%
- Class
- COM NEW
- Share
- 0.6%
- Class
- COM
- Share
- 0.5%
- Class
- COM
- Share
- 0.4%
- Class
- COM
- Share
- 0.4%
- Class
- COM
- Share
- 0.3%
- Class
- ADS
- Share
- 0.3%
The share class is shown on a wider screen.
The 28 largest of 28 positions by value, with holdings of the same security combined. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1855655
- File number
- 028-21950
- Options
- 0 call, 0 put
- In the 25 largest
- 99.0%
- Prior quarter
- $4.89B at 31 March 2026
- Positions opened
- 7
- Positions closed
- 14
Common questions
What are Paradigm BioCapital Advisors’ 13F holdings worth?
$5.34 billion across 28 positions for the quarter ended 30 June 2026.
What is Paradigm BioCapital Advisors’ largest 13F holding?
REVOLUTION MEDICINES INC (COM) was the largest position at $1.19 billion, or 22.3% of reported 13F value, as of 30 June 2026.
How concentrated is Paradigm BioCapital Advisors’ 13F portfolio?
The ten largest positions accounted for 75.2% of reported value and the twenty-five largest for 99.0%, across 28 positions as of 30 June 2026.
Does Form 13F show everything Paradigm BioCapital Advisors manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Paradigm BioCapital Advisors file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.